FUSN

CA36118A1003

Market Closed - Nasdaq Other stock markets 01:30:00 04/06/2024 am IST			5-day change	1st Jan Change
21.55 ^USD	+0.14%		0.00%	+124.25%

04/06	Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete	MT
04/06	Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index	CI

Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Composite Index

June 03, 2024

Fusion Pharmaceuticals Inc. has been Dropped from NASDAQ Composite Index .

Latest news about FUSN PHAR

Fusion Pharmaceuticals Says $2.4 Billion Acquisition by AstraZeneca Unit Is Complete	05/06	MT
Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Biotechnology Index	04/06	CI
AstraZeneca AB completed the acquisition of Fusion Pharmaceuticals Inc. from a group of shareholders.	04/06	CI
Fusion Pharmaceuticals Inc.(NasdaqGS:FUSN) dropped from NASDAQ Composite Index	03/06	CI
Fusion Pharmaceuticals Gets Court Order Approving AstraZeneca Deal	01/06	MT
Fusion Pharmaceuticals Shareholders Approve AstraZeneca Deal	30/05	MT
Fusion Pharmaceuticals Inc. Announces First Patient Dosed in the Phase 2 Portion of the AlphaBreak Trial Evaluating FPI-2265 in Metastatic Castration-Resistant Prostate Cancer	10/05	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	07/05	CI
TD Cowen Downgrades Fusion Pharmaceuticals to Hold	16/04	MT
Fusion Pharmaceuticals Inc. Presents Interim Efficacy and Safety Data from the Phase 2 TATCIST Open-Label Clinical Trial Evaluating FPI-2265	10/04	CI
Fusion Pharmaceuticals Narrows Q4 Loss; Enters Sale Deal With AstraZeneca	21/03	MT
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03	CI
Fusion Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03	CI
B. Riley Downgrades Fusion Pharmaceuticals to Neutral From Buy on Heels of Announced Sale to AstraZeneca, Adjusts PT to $23 From $13	20/03	MT
Bloom Burton Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21.50 From $20	20/03	MT
Fusion Pharmaceuticals Downgraded by RBC to Sector Perform From Outperform, Speculative Risk Removed, Price Target Raised to $21 From $16	20/03	MT
JonesTrading Downgrades Fusion Pharmaceuticals to Hold From Buy	20/03	MT
Sector Update: Health Care Stocks Rise Late Afternoon	20/03	MT
Jefferies Downgrades Fusion Pharmaceuticals to Hold From Buy, Raises Price Target to $21 From $10	20/03	MT
Morgan Stanley Downgrades Fusion Pharmaceuticals to Equalweight From Overweight, Raises Price Target to $21 From $10	20/03	MT
Sector Update: Health Care Stocks Higher in Tuesday Afternoon Trading	20/03	MT
Sector Update: Health Care	20/03	MT
Top Midday Gainers	19/03	MT
Truist Securities Downgrades Fusion Pharmaceuticals to Hold From Buy, Adjusts Price Target to $21 From $11	19/03	MT
Top Stories at Midday: February US Housing Starts Rise; AstraZeneca to Acquire Fusion Pharmaceuticals; IFF to Sell Pharma Solutions Unit; Unilever to Spin Off Ice Cream Unit; MicroStrategy Completes Notes Offering; Super Micro Computer Files Shelf; Nvidia Unveils Latest GPU	19/03	MT

Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its TAT platform is underpinned by its research and insights into the underlying biology of alpha emitting radiopharmaceuticals as well as its differentiated capabilities in target identification, candidate generation, manufacturing and supply chain and development of imaging diagnostics. The Company's lead product candidate is FPI-1434, that utilizes Fast-Clear linker to connect a humanized monoclonal antibody that targets the insulin-like growth factor I receptor (IGF-1R) with alpha emitting isotope actinium-225.

Sector

More about the company